
Job Description: Director or VP of Targeted Alpha Therapy Radiochemistry Research

Type: Full Time

Location: Australia, Europe or United States

Date: Immediate

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited (“Telix”, the “Company”) is an Australian public Company (ASX:TLX) headquartered in Melbourne with operations in Europe, the US and Japan. Our mission is to be a leading, global biopharmaceutical Company in the field of “theranostic” radiopharmaceuticals and the Company is currently developing a mid-late stage pipeline of products in oncology and rare diseases.

Description

Telix is expanding and searching for a Director or VP of Targeted Alpha Therapy Research to contribute to the achievement of the Group’s strategic goals by leading research projects in the field of alpha-emitting radioisotopes and their use in Targeted Alpha Therapy (TAT) within the Telix portfolio. The incumbent will report to the Chief Scientist and will also work closely with other internal R&D members, the preclinical manager and clinical and project teams across multiple disciplines. As a growth area of research for Telix, the initial incumbent will have the opportunity to determine the strategic direction of the company’s targeted alpha strategy by developing, planning and initiating a research theme around alpha-emitting radioisotopes & related technologies.

Key accountabilities for the role will include:

- Leading the TAT research strategy in the company by developing and implementing a long-term research strategy will create platform capabilities & add value to Telix’s proprietary products and pipeline
- Prioritising and driving research projects with a commercial mindset to evaluate, optimise and ultimately deliver meaningful research outcomes
- Leading collaborations and partnerships with strategic partners relating to alpha radioisotope production, radiolabelling and chelator chemistries and preclinical evaluation of alpha-emitting radiopharmaceuticals.
- Ensuring the delivery of ongoing and future projects by building capability through various channels
- Supporting colleagues by providing technical input on the design and interpretation of clinical studies with TAT agents.
- Maintaining an awareness of the current literature, developments in the field and encouraging strategic partnerships with companies or academic groups to identify best industry practice
- Managing program timelines, resources & budgets.

Title and location are negotiable however, to be considered, candidates must have:

- PhD in a quantitative discipline (e.g. chemistry) or equivalent practical experience
- Relevant applied research experience working in radiopharmaceuticals, molecularly-targeted radiation and, ideally with alpha-emitting radioisotopes
- R&D experience in the commercial environment with a solid understanding of the drug development process including preclinical studies, cGMP principles, clinical studies and regulatory processes

- Demonstrated knowledge of the TAT research field including relevant topics of radiochemistry, isotopes (and their supply chain), chelators, targeting agents and radiobiology
- Demonstrable experience managing complex technical research programs and successful 3rd party academic or commercial collaborations
- Commerciality to guide corporate strategy in this area and prioritise key commercial projects.

No agency submissions will be considered for this role.